1633 related articles for article (PubMed ID: 17418686)
1. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
de Zeeuw D
Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
[TBL] [Abstract][Full Text] [Related]
2. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
4. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes.
Donnelly R; Yeung JM; Manning G
J Hypertens Suppl; 2003 Mar; 21(1):S7-12. PubMed ID: 12769161
[TBL] [Abstract][Full Text] [Related]
5. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Circulation; 2004 Aug; 110(8):921-7. PubMed ID: 15302780
[TBL] [Abstract][Full Text] [Related]
6. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
[TBL] [Abstract][Full Text] [Related]
7. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
Cooper ME
J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
[TBL] [Abstract][Full Text] [Related]
8. Losartan in diabetic nephropathy.
Perico N; Ruggenenti P; Remuzzi G
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
[TBL] [Abstract][Full Text] [Related]
9. Microalbuminuria as a target to improve cardiovascular and renal outcomes.
Basi S; Lewis JB
Am J Kidney Dis; 2006 Jun; 47(6):927-46. PubMed ID: 16731288
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
Bakris GL; Toto RD; McCullough PA
J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206
[TBL] [Abstract][Full Text] [Related]
11. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
Ruilope LM
Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
[TBL] [Abstract][Full Text] [Related]
13. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
Agha A; Bashir K; Anwar E
Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
[TBL] [Abstract][Full Text] [Related]
14. New treatment guidelines for a patient with diabetes and hypertension.
Mogensen CE
J Hypertens Suppl; 2003 Mar; 21(1):S25-30. PubMed ID: 12769164
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapeutic strategies in diabetic nephropathy.
Ravera M; Re M; Weiss U; Deferrari L; Deferrari G
J Nephrol; 2007; 20 Suppl 12():S23-32. PubMed ID: 18050139
[TBL] [Abstract][Full Text] [Related]
16. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes.
Ibsen H; Olsen MH; Wachtell K; Borch-Johnsen K; Lindholm LH; Mogensen CE
J Nephrol; 2008; 21(4):566-9. PubMed ID: 18651547
[TBL] [Abstract][Full Text] [Related]
17. Should albuminuria be a therapeutic target in patients with hypertension and diabetes?
de Zeeuw D
Am J Hypertens; 2004 Nov; 17(11 Pt 2):11S-15S; quiz A2-4. PubMed ID: 15539105
[TBL] [Abstract][Full Text] [Related]
18. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
Ravera M; Deferrari L; Ratto E; Vettoretti S; Parodi D; Deferrari G
Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
[TBL] [Abstract][Full Text] [Related]
19. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
20. Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes.
Chuahirun T; Khanna A; Kimball K; Wesson DE
Am J Kidney Dis; 2003 Jan; 41(1):13-21. PubMed ID: 12500217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
